Levine J, Goldberger I, Rapaport A, Schwartz M, Schield C, Elizur A, Belmaker R H, Shapiro J, Agam G
Abarbanel Mental Health Center, Bat Yam, Israel.
Eur Neuropsychopharmacol. 1994 Dec;4(4):487-90. doi: 10.1016/0924-977x(94)90297-6.
Inositol is a key metabolite in the phosphatidylinositol cycle, which is a second messenger system for serotonin-2 receptors that have been implicated in the pathophysiology of schizophrenia. Cerebrospinal fluid inositol levels were measured in 20 schizophrenic patients and 19 age- and sex-matched controls and no difference was found. However, the patients were all neuroleptic-treated. A controlled double-blind crossover trial of 12 g daily of inositol for a month in 12 anergic schizophrenic patients, twice the dose given before in schizophrenia, did not show any beneficial effects. However, the number of patients studied was small and the length of time of inositol administration may not have been sufficient.
肌醇是磷脂酰肌醇循环中的关键代谢物，该循环是血清素-2受体的第二信使系统，而血清素-2受体与精神分裂症的病理生理学有关。对20名精神分裂症患者和19名年龄及性别匹配的对照者的脑脊液肌醇水平进行了测量，未发现差异。然而，这些患者均接受了抗精神病药物治疗。一项针对12名无活力型精神分裂症患者进行的对照双盲交叉试验，给予每日12克肌醇，为期一个月，该剂量是之前在精神分裂症研究中所用剂量的两倍，结果未显示出任何有益效果。然而，所研究的患者数量较少，且肌醇给药的时间长度可能并不足够。
